anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will assess the effect of intraoperative measurement of the urethral length with the Foley catheter in optimization of sling placement in the mid female urethra. Of note, the Foley catheter is well-tolerated, placed routinely during surgery to drain the bladder and has no complications associated with it. Women who have chosen to undergo trans-vaginal tape sling (TVT) for stress urinary incontinence will be asked to enroll in this randomized trial by the study team during their clinic visit. Randomization will be performed by the FPMRS study nurse coordinator after a woman has given her informed consent and meets the study criteria. Twenty women will be randomized to undergo measurement of the urethral length by marking the Foley catheter at the urethral meatus when it is placed at the start of the surgical case. When the catheter is removed, the length from the end of the Foley balloon to the marking at the urethra will be measured as urethral length, the mid urethral point will then be determined by dividing the urethral length be two where the incision of sling placement will be made and twenty women will have our usual pre-operative assessment (which does not include intraoperative measurement of the urethral length with the Foley catheter) for the treatment of symptomatic stress urinary incontinence All women participating in the study will receive an intra-operative 3-D trans-vaginal ultrasound (BK Flex Focus ultrasound with the 8838 transvaginal probe). The image will be stored and reviewed for; urethral length, urethral sphincter complex length and width. All women in the study will have an ultrasound at the end of their surgical procedure and a follow-up ultrasound at 2 weeks post operatively to assess for sling migration. Of note, transvaginal ultrasound is well-tolerated and has no complications associated with it. All ultrasound measurements will be done by a four qualified surgeons, Dr. Elizabeth Mueller Dr. Ahmed Akl, Dr. Tanaka Dune, and Dr. Susanne Taege who have been trained on ultrasound measurements. In addition, women will complete questionnaires assessing their pelvic floor symptoms pre-operatively and at 2 week following surgery. Instruments used will be the Pelvic Floor Disorders Inventory (PFDI), Medical Epidemiologic and Social Aging (MESA) and the Patient Global Impression of Improvement (PGII) \[11, 12\].
PURPOSE: A composition containing Hedyotis diffusa extract is provided to reduce ATL activation in serum and to prevent and treat nonalcoholic fatty liver diseases. CONSTITUTION: A composition for preventing and treating non-alcoholic fatty liver diseases contains 0.1-10 wt% of Hedyotis diffusa extract as an active ingredient. The extract is prepared using water or organic solvent. The nonalcoholic fatty liver disease is nonalcoholic simple steatosis, nonalcoholic steatohepatitis, or nonalcoholic cirrhosis of the liver. A health food for improving liver function contains the extract as an active ingredient. The health food includes beverages, chocolate, food, snack pizza, ramen, noodles, gum, candy, ice cream, alcoholic drinks, vitamin complexes, or health food supplements. [Reference numerals] (AA) Liver tissue neutral fat; (BB) Control group; (CC) Hedyotis diffusa group
A composition for preventing and treating arthritis comprising the extract of Betula platyphylla var. japonica is provided to inhibit edema, pain, production of TNF-alpha(tumor necrosis factor-alpha) and NO(nitric oxide), inflammation, decomposition of proteoglycan and collagen, and activity of MMP-13(matrix metalloproteinnase-13) and MMP-3, and reduce cytotoxicity. The composition for preventing and treating arthritis comprises the extract of Betula platyphylla var. japonica, wherein the Betula platyphylla var. japonica extract is prepared with water or C1-C4 lower alcohol; the arthritis is degenerative arthritis, rheumatoid arthritis or Lupus arthritis; the composition is a pharmaceutical or health food composition; and the daily dosage of the Betula platyphylla var. japonica extract is 0.001-100 mg/kg.
The invention discloses endophytic fungi Septoriella    phragmitis And the application thereof, the strain can produce the eupatorium in the case of liquid fermentation. The strain is preserved in China center for type culture Collection (university of Wuhan) at 9 and 13 days 2022 with a preservation number of CCTCC M20221413. The invention also discloses a method for preparing the eupatorium by using the preserved strain, and culture and fermentation of thalli; extraction of secondary metabolites; and (5) purifying by column chromatography. The invention is advantageous inThe novel strain is provided for producing the eupatorium by microbial fermentation, the period for producing the eupatorium by the strain is short, and the yield of the eupatorium by shake flask fermentation can reach 159.6 mug/L. Eupatorium produced by the strain α The glucosidase and PTP1B inhibition activity tests showed different degrees of inhibition activity at concentrations of 5. Mu.g/ml, with inhibition rates of 22.34% and 51.32%, respectively. The eupatorium has better effect α -glucosidase and PTP1B inhibition, as lead compounds for dual targets against diabetes.
Osteoporosis (OP), which is characterized by a decrease in bone density and increased susceptibility to fractures, is closely linked to the gut microbiota (GM). It is increasingly realized that the GM plays a key role in the maintenance of the functioning of multiple organs, including bone, by producing bioactive metabolites such as short-chain fatty acids (SCFA). Consequently, imbalances in the GM, referred to as dysbiosis, have been identified with a significant reduction in beneficial metabolites, such as decreased SCFA associated with increased chronic inflammatory processes, including the activation of NF-κB at the epigenetic level, which is recognized as the main cause of many chronic diseases, including OP. Furthermore, regular or long-term medications such as antibiotics and many non-antibiotics such as proton pump inhibitors, chemotherapy, and NSAIDs, have been found to contribute to the development of dysbiosis, highlighting an urgent need for new treatment approaches. A promising preventive and adjuvant approach is to combat dysbiosis with natural polyphenols such as resveratrol, which have prebiotic functions and ensure an optimal microenvironment for beneficial GM. Resveratrol offers a range of benefits, including anti-inflammatory, anti-oxidant, analgesic, and prebiotic effects. In particular, the GM has been shown to convert resveratrol, into highly metabolically active molecules with even more potent beneficial properties, supporting a synergistic polyphenol-GM axis. This review addresses the question of how the GM can enhance the effects of resveratrol and how resveratrol, as an epigenetic modulator, can promote the growth and diversity of beneficial GM, thus providing important insights for the prevention and co-treatment of OP.
PROBLEM TO BE SOLVED: To accurately dose a prescribed amount of medical powder to a patient by preventing external spillage of the medical powder by air reversed through an inhalation port. SOLUTION: A cap 13 is formed to open or close a capsule housing chamber, a common air path 18 is formed on the cap 13 to make inflow side air paths 9 and auxiliary air paths 11 communicate with the side of atmospheric air while a reflux preventing valve 22 is disposed in the course of the common air path 18. The passage resistance of each auxiliary air path 11 is set smaller than that of each of the air paths 9 and 10. When air is inhaled at an inhalation port 4, the reflux preventing valve 22 is opened to allow sucking of medical powder in the capsule through the air paths 9 and 10. When air is reversed through the inhalation port 4, air is made to pass through the auxiliary air path 11 quickly to close the reversion preventing valve 22, thereby preventing outflow of the air in the air paths 9 and 10 to the atmospheric air.  This also can prevent slipping of the capsule during the dosage by closing the cap 13.
The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
The web-supported interactive nursing program intervention will last 4 weeks. In the first week of the training, the identity and causes of the disease, which is one of the sub-dimensions of the perception of illness, will be emphasized, and the themes of misperception determined in this field through qualitative study will be emphasized. In the second week, they will be asked to look at training sessions that discuss perceptions of the illness's timeline and consequences. In the last two weeks of the training, they will be asked to attend the trainings for the control of Fibromyalgia symptoms. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times). Data collection forms will be applied to the intervention group 3 times before starting the web-based interactive nurse program, at the end of the program (in the 1st month) and then at the end of the 2nd month.
OBJECTIVE: Olfactory dysfunction (OD) represents a frequent complaint in general population and especially in patients with chronic sinonasal diseases. The aim of this study was the cross-cultural adaptation and validation of the Self-reported Mini Olfactory Questionnaire (Self-MOQ) into Italian.
METHODS: One hundred fifty patients affected by chronic sinonasal diseases and reporting hyposmia were enrolled. Other 150 normosmic subjects without inflammatory or neoplastic sinonasal disorders were used as a control group. The Short-form 36 (SF-36) questionnaire was used for clinical validity.
RESULTS: Cronbach's alpha coefficient was 0.825. The test-retest reliability was excellent. The good correlation between the Self-MOQ and the Visual Analogue Scale scores (p < 0.05) demonstrated the construct validity of the questionnaire. The Self-MOQ was able to distinguish between subjects with or without OD (p < 0.05). Higher Self-MOQ score was found in case of nasal obstruction and posterior rhinorrhoea (p < 0.05). Self-MOQ showed significant correlation with SF-36 general health, SF-36 role functioning/physical, and SF-36 pain (p < 0.05).
CONCLUSIONS: The Italian version of the Self-MOQ showed good internal consistency, test-retest reliability, construct, and clinical validity.
Quetiapine 50mg in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
Insulin Lispro has been shown to be equipotent to human insulin on a molar basis. One unit of Insulin Lispro has the same glucose-lowering effect as one unit of regular human insulin. Studies in normal volunteers and patients with diabetes demonstrated that Insulin Lispro has a more rapid onset of action and a shorter duration of activity than regular human insulin when given subcutaneously. 

The time course of action of insulin and insulin analogs, such as Insulin Lispro, may vary considerably in different individuals or within the same individual. The parameters of Insulin Lispro activity (time of onset, peak time, and duration) as designated in Figure 1 should be considered only as general guidelines. The rate of insulin absorption, and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables [see Warnings and Precautions (5.2)]. 

Figure 1: Blood Glucose Levels After Subcutaneous Injection of Regular Human Insulin or Insulin Lispro (0.2 unit/kg) Immediately Before a High Carbohydrate Meal in 10 Patients with Type 1 Diabetesa. 

a Baseline insulin concentration was maintained by infusion of 0.2 mU/min/kg human insulin. 

Intravenous Administration — The glucose lowering effect of intravenously administered Insulin Lispro was tested in 21 patients with type 1 diabetes. For the study, the patients' usual doses of insulin were held and blood glucose concentrations were allowed to reach a stable range of 200 to 260 mg/dL during a one to three hours run-in phase. The run-in phase was followed by a 6-hour assessment phase. During the assessment phase, patients received intravenous Insulin Lispro at an initial infusion rate of 0.5 units/hour. The infusion rate of Insulin Lispro could be adjusted at regular timed intervals to achieve and maintain blood glucose concentrations between 100 to 160 mg/dL. 

The mean blood glucose levels during the assessment phase for patients on Insulin Lispro therapy are summarized below in Table 4. All patients achieved the targeted glucose range at some point during the 6-hour assessment phase. At the endpoint, blood glucose was within the target range (100 to 160 mg/dL) for 17 of 20 patients treated with Insulin Lispro. The average time (±SE) required to attain near normoglycemia was 129 ± 14 minutes for Insulin Lispro.
1. Amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1-2 of the naturally-occurring RANTES having amino acid SEQ ID No:2 and having chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. 2. Amino-terminally truncated MCP-2 according to one or more of the preceding claims, in a glycosylated form. 3. DNA molecules coding for the amino-terminally truncated RANTES according to claims 1 or 2. 4. An expression vector which comprises the DNA molecule according to claim 3. 5. A host cell comprising the expression vector according to claim 4. 6. A recombinant process for preparing a protein according to claim 1 or 2, comprising cells culturing according to claim 5 in an appropriate culture medium and isolating the expression product. 7. Use of a protein according to claims 1 or 2 as a medicament the therapy of which is based on the chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. 8. Use of a protein according to claims 1 or 2 in the manufacture of a medicament the therapy and/or diagnosis of diseases, the therapy of which is based on the chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. 9. Use of a protein according to claim 8 in the manufacture of a medicament for the treatment of inflammatory diseases, HIV-infection, angiogenisis- and hematopoiesis-related diseases, and tumors. 10. A pharmaceutical composition comprising the protein according to any of the claims 1 or 2 together with one or more pharmaceutically acceptable carriers and/or excipients, the therapy of which is based on the chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES.
PURPOSE:To provide an antitumor agent containing a compound such as 4-(3- methyl-2-butenyl)-1,2-diphenyl-3,5-pyrazolidinedione, etc. as an active component, effective to animal or human tumor, and exhibiting the effect to decease the tumor cells and improve the life prolongation rate, etc. CONSTITUTION:The objective agent contains the compound of formula (R and R1 are H or halogen), e.g. 4-(3-methyl-2-butenyl)-1,2-diphenyl-3,5-pyrazolidinedione, etc. as an active component. The antitumor agent is administered orally in the form of powder, particle, granule, etc. or parenterally in the form of injection solution sealed in an ampule, bottle, etc. or suppository or ointment. The amount of the active component in the agent is generally 0.01-100wt%, preferably 0.05-80wt%.
Anastrozole, an aromatase inhibitor, induces painful musculoskeletal symptoms, which affect patients' quality of life and lead to therapy discontinuation. Efforts have been made to understand the mechanisms involved in these painful symptoms to manage them better. In this context, we explored the role of the Transient Receptor Potential Vanilloid 4 (TRPV4), a potential transducer of several nociceptive mechanisms, in anastrozole-induced musculoskeletal pain in mice. Besides, we evaluated the possible sensibilization of TRPV4 by signalling pathways downstream, PLC, PKC and PKCε from kinin B2 (B2R) and B1 (B1R) receptors activation in anastrozole-induced pain. Anastrozole caused mechanical allodynia and muscle strength loss in mice. HC067047, TRPV4 antagonist, reduced the anastrozole-induced mechanical allodynia and muscle strength loss. In animals previously treated with anastrozole, the local administration of sub-nociceptive doses of the TRPV4 (4α-PDD or hypotonic solution), B2R (Bradykinin) or B1R (DABk) agonists enhanced the anastrozole-induced pain behaviours. The sensitizing effects induced by local injection of the TRPV4, B2R and B1R agonists in animals previously treated with anastrozole were reduced by pre-treatment with TRPV4 antagonist. Furthermore, inhibition of PLC, PKC or PKCε attenuated the mechanical allodynia and muscle strength loss induced by TRPV4, B2R and B1R agonists. The generation of painful conditions caused by anastrozole depends on direct TRPV4 activation or indirect, e.g., PLC, PKC and PKCε pathways downstream from B2R and B1R activation. Thus, the TRPV4 channels act as sensors of extracellular and intracellular changes, making them potential therapeutic targets for alleviating pain related to aromatase inhibitors use, such as anastrozole.
The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin. The methods include determining the identity and prevalence of the bacterial community in the gastrointestinal (Gl) tract. In certain embodiments, the microbiome comprises the Gl tract microbiome. In certain embodiments, the microbiome comprises the Gl tract bacterial population. In certain embodiments, the microbiome comprises stool bacterial. The methods include analysis of the identity of the bacterial community in the gastrointestinal (Gl) microbiome to produce a profile of diversity of the bacterial communities.
AIMS: We aimed to analyse serious cardiac adverse drug reactions to COVID-19 vaccines from the Europe-wide EudraVigilance database.
METHODS AND RESULTS: In this retrospective, cross-sectional study, the EudraVigilance database was searched to identify suspected serious cardiac post-vaccination adverse drug reactions to COVID-19 vaccines. This data was coupled with the number of total vaccine doses administered in the European Economic Area for Comirnaty (Pfizer BioNTech), Spikevax (Moderna), Vaxzevria (AstraZeneca), Jcovden (Janssen), Nuvaxovid (Novavax), products, available from the European Centre for Disease Prevention and Control 'Vaccine Tracker' database. The analysis included 772 228 309 administered doses of eligible vaccines from the 'Vaccine Tracker' database and 86 051 eligible records of cardiac adverse drug reactions from the EudraVigilance database. The frequency of most of the investigated adverse drug reactions was very rare (<1/10 000 i.e. <100/1 000 000 doses). The lowest risk of any serious cardiac adverse drug reactions was noticed for vaccination with Comirnaty (135.5 per million doses), while Spikevax, Jcovden, Vaxzevria, and Nuvaxovid were characterized by higher risk (respectively, 140.9, 194.8, 313.6, and 1065.2 per million doses). The most common complications of vaccinations included syncope, arrhythmia, tachycardia, palpitations, angina pectoris, hypertension, myocarditis, thrombosis, and pulmonary embolism.
CONCLUSION: The risk of serious cardiac adverse drug reactions to COVID-19 vaccines is low and the benefit of active immunization against that disease seems to outweigh the potential risk of serious post-vaccination cardiac adverse drug reactions.
Intrusive trauma memories are a hallmark of posttraumatic stress disorder (PTSD), and the least treatment responsive. Thus, revealing neurocognitive mechanisms associated with intrusive trauma memories has been indexed a priority. Prior work shows that targeting hippocampal circuitry modulates functional connectivity among distributed cortical-hippocampal network regions and alters memory performance in healthy participants. In the current clinical trial we test hypotheses on the clinical effects of such stimulation in a two-arms randomized controlled trial: Trauma memory reactivation + targeted hippocampal transcranial magnetic stimulation TMS (R-H-TMS) and Trauma memory reactivation + Control TMS (over the SMA; R-C-TMS). We will test a) Hippocampus seed-based connectivity patterns - revealing the impact of the targeted stimulation on extended memory brain networks; and b) frequency and severity of intrusive memory symptoms. The R-H-TMS vs. R-C-TMS contrast will speak to specificity of the noted effects to hippocampal stimulation.
LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.

Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an ICS is contraindicated. Use SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS. Do not use SEREVENT DISKUS for patients whose asthma is adequately controlled on low- or medium-dose ICS.

Pediatric and Adolescent Patients

Available data from controlled clinical trials suggest that LABA as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients. For pediatric and adolescent patients with asthma who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs. In cases where use of a separate ICS and a LABA is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured, a fixed-dose combination product containing both an ICS and a LABA is recommended.

The Salmeterol Multicenter Asthma Research Trial (SMART) was a large 28-week placebo-controlled U.S. trial comparing the safety of salmeterol (SEREVENT Inhalation Aerosol) with placebo, each added to usual asthma therapy, that showed an increase in asthma-related deaths in subjects receiving salmeterol [see Clinical Studies (14.1)]. Given the similar basic mechanisms of action of beta2-agonists, the findings seen in the SMART trial are considered a class effect.

A 16-week clinical trial performed in the United Kingdom, the Salmeterol Nationwide Surveillance (SNS) trial, showed results similar to the SMART trial. In the SNS trial, the rate of asthma-related death was numerically, though not statistically significantly, greater in subjects with asthma treated with salmeterol (42 mcg twice daily) than those treated with albuterol (180 mcg 4 times daily) added to usual asthma therapy.

The SNS and SMART trials enrolled subjects with asthma. Available data do not suggest an increased risk of death with use of LABA in patients with COPD.